CRISPR Therapeutics AG (CRSP): Price and Financial Metrics
Today's Latest Price: $91.82 USD
Oct 30 4:00pm Add CRSP to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
CRSP Stock Summary With a price/sales ratio of 87.99, CRISPR Therapeutics AG has a higher such ratio than 97.03% of stocks in our set. Over the past twelve months, CRSP has reported earnings growth of 1,884.94%, putting it ahead of 99.08% of US stocks in our set. Revenue growth over the past 12 months for CRISPR Therapeutics AG comes in at -63.63%, a number that bests just 2.63% of the US stocks we're tracking. Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are ZYME, FATE, NKTR, ARVN, and CLLS. CRSP's SEC filings can be seen here. And to visit CRISPR Therapeutics AG's official web site, go to www.crisprtx.com.
CRSP Price/Volume Stats
CRISPR Therapeutics AG (CRSP) Company Bio
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.
CRSP Latest News Stream
All News Types
Barron's Commentary Corp. News Cramer Debt Offering Earnings Hedge Fund IPOs Mgmt Change New Coverage (Bearish) New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering Upgrade
Loading, please wait...
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
The European Medicines Agency has granted Priority Medicines ((PRIME)) designation to CTX001, an autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of severe sickle cell disease ((SCD)).CTX001 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics ([[CRSP]] -1.2%) and Vertex ([[VRTX]] -0.5%).PRIME status provides for enhanced development support and...
The following slide deck was published by CRISPR Therapeutics AG in conjunction with this event....
CRSP stock has pulled back 13% in the last two sessions on no news. The dip allows investors into a strong long-term story at a lower price.
CRISPR Therapeutics Stock Shows It Has Good Genes in Its Charts…CRSP
Since its initial discovery as a genetic reprogramming tool in 2012, CRISPR has widely been regarded as a breakthrough scientific discovery and quickly become one of the hottest new biotechnologies…
Read More 'CRSP' Stories Here
CRSP Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8243 seconds.